Weight loss medications such as Ozempic, Rybelsus, and Wegovy are rapidly reshaping the treatment landscape for both type 2 diabetes and obesity, but their impact on individuals with eating disorders remains a complicated and controversial subject. While some patients have reported fewer binge-eating episodes after starting GLP-1 medications, others have experienced a disturbing resurgence in disordered eating behaviors. As the popularity of these drugs continues to rise, health professionals are urging more research, better patient screening, and a deeper understanding of the psychological effects these medications may carry.
Penny Gautreaux, who took Rybelsus to manage her type 2 diabetes, said that despite an initial warning from her doctor, she quickly experienced serious gastrointestinal discomfort and a profound disinterest in food. “The severity of physical side effects, along with the complete disinterest in food, was simply too much for me to deal with and maintain my recovery,” Gautreaux told Health. As someone who had struggled with disordered eating in the past, the rapid weight loss triggered a familiar and dangerous mindset, prompting her to stop the medication altogether.
Clinicians such as Dr. Elizabeth Wassenaar from the Eating Recovery Center have observed similar cases. She explained that GLP-1 users who are in recovery from eating disorders have sometimes found themselves relapsing, in some instances even developing complications like low blood pressure or a dangerously slow heart rate. Dr. Brad Smith, chief medical officer at Accanto Health, added that these medications can heighten obsessive food-related thoughts for patients with conditions like bulimia nervosa or anorexia, reinforcing unhealthy behaviors.
There are also patients who initially sought out GLP-1 drugs unaware of their own vulnerability. A 24-year-old man, referred to as Jerry, shared that he began obsessing over minor details of his meals while on Ozempic. Only after entering treatment did he learn he had atypical anorexia, a diagnosis that came as a surprise. Speaking to Health, he said the recovery program helped him understand his mental health and the drug’s real impact, revealing how little he was prepared by his doctor for the medication’s effects on his appetite and mindset.
Interestingly, some studies suggest that GLP-1 medications may offer therapeutic benefits for individuals with binge eating disorder. A 2025 review involving 182 participants found a reduction in binge-eating episodes, which researchers attributed to the drug’s influence on hunger and reward pathways in the brain. “For an eating disorder like binge eating, the drug may actually help the patient because GLP-1s reduce food noise,” said Dr. Sue Decotiis, a New York-based weight-loss specialist, in an interview with Health. This was the experience of Helen Purves, who began seeing improvements in her symptoms after switching to Mounjaro, noting a significant drop in obsessive food thoughts.
Even so, experts caution that the studies are too small and too short in duration to draw definitive conclusions. “While there’s theoretical evidence that GLP-1s may benefit people who struggle with compulsive eating behaviors, we still don’t know the long-term implications,” Dr. Wassenaar told Health. Moreover, none of the GLP-1 medications are FDA-approved for treating eating disorders. Pharmaceutical companies like Novo Nordisk and Eli Lilly have stated in emails to Health that their products are not currently indicated or being studied for this use, although routine safety reviews are ongoing.
Looking ahead, medical professionals stress the importance of screening patients for signs of disordered eating before prescribing GLP-1s and ensuring they receive mental health support alongside physical treatment. Dr. Alexandra Sowa, author of The Ozempic Revolution, emphasized that GLP-1 users often require more guidance than they anticipate. Meanwhile, concerns are mounting about the growing use of compounded, off-brand GLP-1 medications distributed by telehealth services, prompting regulatory responses from the FDA to crack down on these unapproved options.
As weight loss medications become a cultural and medical phenomenon, the wider conversation must also evolve. “Does the weight loss medication frenzy intentionally convey a message that all people can—and should—be smaller?” asked Dr. Smith in his comments to Health. “These are questions to grapple with as the story of GLP-1 medications and those yet to come unfolds.”
